NEW YORK – Foundation Medicine announced on Friday its FoundationOne CDx test received approval from the US Food and Drug Administration for use with larotrectinib (Bayer's Vitrakvi) to help identify cancer patients with neurotrophic receptor tyrosine kinase fusions.